Navigation Links
Melatonin pre-treatment is a factor that impacts stem cell survival after transplantation

Putnam Valley, NY. -- When melatonin, a hormone secreted by the pineal gland, was used as a pre-treatment for mesenchymal stem cells (MSCs) prior to their transplantation into the brains of laboratory animals to repair damage from stroke, researchers in China found that the stem cells survived longer after transplantation. Previous studies had shown that 80 percent of transplanted MSCs died within 72 hours of transplantation. By contrast, the melatonin pre-treatment "greatly increased" cell survival, said the researchers.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at

The pineal gland is a small endocrine gland located in the center of the brain, but outside of the bloodbrain barrier. The melatonin it secretes acts as a signal and forms part of the system that regulates the sleepwake cycle by chemically causing drowsiness and lowering body temperature. Melatonin is also known to be a powerful antioxidant and has been used clinically to treat sleep disorders.

In this study, the researchers used a melatonin pre-treatment on MSCs they harvested from the laboratory animals that had been chemically modeled with ischemic brain injury (stroke). Previous studies had shown that MSCs "express" melatonin receptors M1 and M2.

"Mesenchymal cells can be harvested from self-donors (autologous) without ethical concerns," said study co-author Dr. Guo-Yuan Yang of the Neuroscience and Neuroengineering Research Center at the Shanghai Jiao Tong University in Shanghai, China. "Studies have shown that MSCs differentiate into various cells and can, upon transplantation, improve functional recovery after ischemic brain injury. In this study we used laboratory rats chemically modeled with stroke and tried to determine if pretreatment with melatonin would promote cell survival."

Researchers transplanted pre-treated MSCs into one group of brain injured rats and also used a control group of animals that received MSCs that were not pre-treated with melatonin.

Study results demonstrated that the melatonin pre-treated MSCs had "enhanced survival under oxidative stimulation by activating the Erk1/2 pathway" (extracellular signal-regulated kinases), a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell.

"Our study demonstrated increased survival of transplanted MSCs and revealed that the pre-treated MSCs reduced infarct volume and improved neurobehavioral outcomes for at least 14 days," said Dr. Yang.

The researchers noted that the impact of pre-treatment with melatonin was not MSC differentiation, and that development into mature brain cells was not an important factor in the beneficial effects derived from transplantation of either the untreated or the pre-treated cells. They suggested that the transplantation of MSCs pre-treated with melatonin may have a positive impact on the secretion of vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulate vascular and blood vessel growth that can help restore the oxygen supply to tissues when blood circulation is inadequate.

"Our study demonstrated that melatonin pre-treatment promoted MSC survival in the laboratory setting and augmented the therapeutic efficiency of MSCs in the rat brain. The protective effect of melatonin is achieved by activation of the Erk1/2 pathway," they concluded. "This strategy of pre-treating stem cells may represent a safe approach for improving the beneficial effects of stem cell therapy for cerebral ischemia."

"It is important to identify factors that can impact on the survival of stem cells following their potential therapeutic use for a variety of neurological disorders", said Dr. Shinn-Zong Lin, professor of Neurosurgery and superintendent at the China Medical University Hospital, Beigang, Taiwan. "This study suggests that melatonin pretreatment could be a factor and its role should be explored further with other disease models and other cell types".


Contact: Robert Miranda
Cell Transplantation Center of Excellence for Aging and Brain Repair

Related biology news :

1. FASEB SRC announces conference registration open for: Melatonin Biology: Actions & Therapeutics
2. Pitt team finds melatonin delays ALS symptom onset and death in mice
3. Environmental factors in Tiny Tims near fatal illness
4. Soy-based S-equol supplement reduces metabolic syndrome risk factors
5. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
6. Impaired recovery of Atlantic cod -- forage fish or other factors?
7. Longer sleep times may counteract genetic factors related to weight gain
8. Molecule found that inhibits estrogen, key risk factor for endometrial and breast cancers
9. Time, place and how wood is used are factors in carbon emissions from deforestation
10. SRI Sarnoffs Iris on the MoveĀ® N-Glanceā„¢ Identification System Receives Lenel Factory Certification
11. Growth factor in stem cells may spur recovery from MS
Post Your Comments:
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
Breaking Biology Technology: